Stock MEGA MEGA LIFESCIENCES
Add to a list
To use this feature you must be a member
Log inSign up

Financials Mega Lifesciences

Equities

MEGA

TH4984010009

Pharmaceuticals

End-of-day quote Thailand S.E.
Other stock markets
 06:00:00 2024-05-01 pm EDT 		5-day change 1st Jan Change
40.5 THB -1.22% Intraday chart for Mega Lifesciences -1.82% +0.62%
Feb. 23 Transcript : Mega Lifesciences Public Company Limited, 2023 Earnings Call, Feb 23, 2024
Feb. 22 Mega Lifesciences Public Company Limited Proposes Dividend for the Year Ended December 31, 2023, Payable on April 22, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 22,669 31,169 44,029 40,760 35,093 35,311 - -
Enterprise Value (EV) 1 22,104 30,451 41,666 38,309 35,093 32,063 31,539 31,659
P/E ratio 19.8 x 22.3 x 22.6 x 18.2 x 17.6 x 14.4 x 13.4 x 12.5 x
Yield 2.77% 2.52% 2.1% 3.44% - 4.28% 4.58% 4.99%
Capitalization / Revenue 2.03 x 2.47 x 3.08 x 2.6 x 2.24 x 2.19 x 2.07 x 1.98 x
EV / Revenue 1.98 x 2.41 x 2.91 x 2.44 x 2.24 x 1.99 x 1.85 x 1.78 x
EV / EBITDA 13.7 x 15.6 x 17.2 x 13 x 11 x 10.1 x 9.22 x 8.68 x
EV / FCF 22.9 x 21.8 x 16.2 x 22.6 x - 13.3 x 12.7 x 12.1 x
FCF Yield 4.37% 4.58% 6.18% 4.42% - 7.51% 7.89% 8.29%
Price to Book 3.67 x 4.48 x 5.5 x 4.64 x - 3.47 x 3.1 x 3 x
Nbr of stocks (in thousands) 871,870 871,870 871,870 871,870 871,870 871,870 - -
Reference price 2 26.00 35.75 50.50 46.75 40.25 40.50 40.50 40.50
Announcement Date 2/24/20 2/22/21 2/23/22 2/25/23 2/22/24 - - -
1THB in Million2THB
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 11,179 12,643 14,301 15,686 15,681 16,144 17,035 17,827
EBITDA 1 1,613 1,951 2,426 2,953 3,190 3,189 3,422 3,648
EBIT 1 1,451 1,695 2,305 2,681 2,904 2,871 3,074 3,279
Operating Margin 12.98% 13.41% 16.12% 17.09% 18.52% 17.78% 18.05% 18.4%
Earnings before Tax (EBT) 1 1,299 1,623 2,277 2,595 2,262 2,882 3,122 3,365
Net income 1 1,139 1,393 1,947 2,242 1,993 2,430 2,624 2,821
Net margin 10.18% 11.02% 13.61% 14.29% 12.71% 15.05% 15.4% 15.83%
EPS 2 1.310 1.600 2.230 2.570 2.290 2.814 3.032 3.228
Free Cash Flow 1 966.6 1,395 2,575 1,692 - 2,408 2,488 2,626
FCF margin 8.65% 11.03% 18.01% 10.79% - 14.92% 14.6% 14.73%
FCF Conversion (EBITDA) 59.91% 71.49% 106.16% 57.3% - 75.53% 72.68% 71.97%
FCF Conversion (Net income) 84.9% 100.17% 132.29% 75.49% - 99.12% 94.8% 93.06%
Dividend per Share 2 0.7200 0.9000 1.060 1.610 - 1.733 1.855 2.020
Announcement Date 2/24/20 2/22/21 2/23/22 2/25/23 2/22/24 - - -
1THB in Million2THB
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1
Net sales 1 5,710 6,865 3,999 3,311 3,820 3,930 4,052 3,884 3,728 3,992 7,720 3,803 4,158 3,749
EBITDA 815.6 1,115 723.5 587.3 791.8 669.2 - 667.7 - - 1,525 - 874.3 -
EBIT 1 - - 741.9 553.3 724.9 590.2 769.5 599.6 616.1 786.5 1,385 718.1 801.1 671
Operating Margin - - 18.55% 16.71% 18.98% 15.02% 18.99% 15.44% 16.52% 19.7% 17.94% 18.88% 19.27% 17.9%
Earnings before Tax (EBT) 1 706.8 993 736.2 547.7 716.6 631.9 778.5 467.6 526 571 - 633.1 531.6 636.3
Net income 1 623.3 837.8 612.6 496.4 614 569.5 658.3 399.8 453 530.9 983.9 535.5 473.2 487.5
Net margin 10.92% 12.2% 15.32% 14.99% 16.07% 14.49% 16.24% 10.29% 12.15% 13.3% 12.74% 14.08% 11.38% 13%
EPS 2 0.7100 0.9600 0.7000 0.5664 0.7000 0.6500 0.7600 0.4600 0.5200 0.6100 1.130 0.6100 0.5500 0.5900
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 8/14/20 8/16/21 11/15/21 2/23/22 5/13/22 8/11/22 11/14/22 2/25/23 5/12/23 8/11/23 8/11/23 11/13/23 2/22/24 -
1THB in Million2THB
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 565 718 2,363 2,451 - 3,248 3,772 3,652
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 967 1,395 2,575 1,692 - 2,408 2,488 2,626
ROE (net income / shareholders' equity) 19.1% 21.2% 26% 26.7% - 25% 24.7% 25.4%
ROA (Net income/ Total Assets) 11.3% 12.6% 15.7% 16.1% - 16.5% 16.5% 17.4%
Assets 1 10,070 11,061 12,414 13,959 - 14,771 15,903 16,214
Book Value Per Share 2 7.080 7.980 9.180 10.10 - 11.70 13.10 13.50
Cash Flow per Share 2 1.720 2.330 3.040 3.420 - 3.180 3.120 3.090
Capex 1 529 234 151 305 - 313 312 354
Capex / Sales 4.73% 1.85% 1.06% 1.94% - 1.94% 1.83% 1.98%
Announcement Date 2/24/20 2/22/21 2/23/22 2/25/23 2/22/24 - - -
1THB in Million2THB
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Mega Lifesciences

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
40.5 THB
Average target price
49.56 THB
Spread / Average Target
+22.38%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
MEGA LIFESCIENCES Stock Mega Lifesciences
+1.86% 957M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 681B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+20.33% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 325B
ABBVIE INC. Stock AbbVie Inc.
+3.77% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.42% 235B
NOVARTIS AG Stock Novartis AG
+4.34% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-11.41% 189B
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MEGA Stock
  4. Financials Mega Lifesciences